A detailed history of North Crest Asset Manangement, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, North Crest Asset Manangement, LLC holds 10,470 shares of EXEL stock, worth $278,920. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,470
Previous 10,400 0.67%
Holding current value
$278,920
Previous $246,000 4.47%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

BUY
$20.34 - $23.73 $1,423 - $1,661
70 Added 0.67%
10,470 $235,000
Q1 2024

Apr 15, 2024

SELL
$20.17 - $23.93 $17,749 - $21,058
-880 Reduced 7.8%
10,400 $246,000
Q4 2022

Feb 01, 2023

SELL
$14.96 - $17.39 $4,428 - $5,147
-296 Reduced 2.56%
11,280 $180,000
Q3 2022

Oct 17, 2022

BUY
$15.68 - $22.27 $4,641 - $6,591
296 Added 2.62%
11,576 $182,000
Q1 2022

Apr 18, 2022

BUY
$17.03 - $22.67 $192,098 - $255,717
11,280 New
11,280 $256,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.57B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track North Crest Asset Manangement, LLC Portfolio

Follow North Crest Asset Manangement, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of North Crest Asset Manangement, LLC, based on Form 13F filings with the SEC.

News

Stay updated on North Crest Asset Manangement, LLC with notifications on news.